4.5 Article

Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid

期刊

NEUROBIOLOGY OF AGING
卷 93, 期 -, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2020.03.012

关键词

Alzheimer's disease (AD); Cerebrospinal fluid (CSF); Polygenic risk scores (PGRS); Complement cascades; Cell adhesion molecules; Cytokines

资金

  1. Stichting Alzheimer Nederland
  2. Stichting VUmc fonds
  3. EU-PRISM Project (Psychiatric Ratings using Intermediate Stratified Markers) from the Innovative Medicines Initiative 2 Joint Undertaking [115916]
  4. European Union's Horizon 2020 research and innovation program
  5. European Federation of Pharmaceutical Industries and Associations (EFPIA)
  6. Alzheimer's Disease Neuroimaging Initiative (ADNI)
  7. National Institutes of Health [U01 AG024904]
  8. DOD ADNI (Department of Defense award) [W81XWH-12-2-0012]
  9. National Institute on Aging
  10. National Institute of Biomedical Imaging and Bioengineering
  11. AbbVie
  12. Alzheimer's Association
  13. Alzheimer's Drug Discovery Foundation
  14. Araclon Biotech
  15. BioClinica, Inc
  16. Biogen
  17. Bristol-Myers Squibb Company
  18. CereSpir, Inc
  19. Cogstate
  20. Eisai Inc
  21. Elan Pharmaceuticals, Inc
  22. Eli Lilly and Company
  23. EuroImmun
  24. F. Hoffmann-La Roche Ltd
  25. company Genentech, Inc
  26. Fujirebio
  27. GE Healthcare
  28. IXICO Ltd
  29. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  30. Johnson & Johnson Pharmaceutical Research & Development LLC.
  31. Lumosity
  32. Lundbeck
  33. Merck Co, Inc
  34. Meso Scale Diagnostics, LLC.
  35. NeuroRx Research
  36. Neurotrack Technologies
  37. Novartis Pharmaceuticals Corporation
  38. Pfizer Inc
  39. Piramal Imaging
  40. Servier
  41. Takeda Pharmaceutical Company
  42. Transition Therapeutics
  43. Canadian Institutes of Health Research
  44. French National Foundation on Alzheimer's disease and related disorders
  45. LABEX (laboratory of excellence program investment for the future) DISTALZ grant
  46. Inserm
  47. Institut Pasteur de Lille
  48. Universite de Lille 2
  49. Lille University Hospital
  50. Medical Research Council [503480]
  51. Alzheimer's Research UK [503176]
  52. Wellcome Trust [082604/2/07/Z]
  53. German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, BMBF): Competence Network Dementia (CND) grant [01GI0102, 01GI0711, 01GI0420]
  54. NIH/NIA grant [R01 AG033193]
  55. NIA [AG081220]
  56. AGES contract [N01-AG-12100]
  57. NHLBI [R01 HL105756]
  58. Icelandic Heart Association
  59. Erasmus Medical Center
  60. Erasmus University
  61. Alzheimer's Association grant [ADGC-10-196728]
  62. NIH/NIA grants [U01 AG032984, U24 AG021886, U01 AG016976]
  63. European Commission
  64. Dutch Research Council (ZonMW)
  65. Association of Frontotemporal Dementia/Alzheimer's Drug Discovery Foundation
  66. Alzheimer Netherlands
  67. Probiodrug
  68. Janssen prevention center
  69. Boehringer
  70. Brains online
  71. Axon Neurosciences
  72. EIP pharma
  73. Roche
  74. Piramal
  75. Dutch brain foundation
  76. EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant) [115372]
  77. ZonMW Memorabel grant program [73305056, 733050824]

向作者/读者索取更多资源

Genetic factors play a major role in Alzheimer's disease (AD) pathology, but biological mechanisms through which these factors contribute to AD remain elusive. Using a cerebrospinal fluid (CSF) proteomic approach, we examined associations between polygenic risk scores for AD (PGRS) and CSF proteomic profiles in 250 individuals with normal cognition, mild cognitive impairment, and AD-type dementia from the Alzheimer's Disease Neuroimaging Initiative. Out of 412 proteins, 201 were associated with PGRS. Hierarchical clustering analysis on proteins associated with PGRS at different single-nucleotide polymorphism p-value inclusion thresholds identified 3 clusters: (1) a protein cluster correlated with highly significant single-nucleotide polymorphisms, associated with amyloid-beta pathology and complement cascades; (2) a protein cluster associated with PGRS additionally including variants contributing to modest risk, involved in neural injury; (3) a protein cluster that also included less strongly associated variants, enriched with cytokine-cytokine interactions and cell adhesion molecules. These findings suggest that CSF protein levels reflect varying degrees of genetic liability for AD and may serve as a tool to investigate biological mechanisms in AD. (C) 2020 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据